Who Owns AbCellera Biologics Stock?
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 36.80%
- Held by insiders
- 21.74%
- Institutional holders
- 192
- Institutions 36.8%
- Insiders 21.7%
- Public and other 41.5%
Who owns AbCellera Biologics stock?
Institutional investors own about 36.8% of AbCellera Biologics's shares, spread across 192 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 21.74% of ABCL.
The largest institutional holders are Baker Bros. Advisors, LP (10.11%), Capital World Investors (4.16%) and Two Sigma Investments, LP (3.58%). Together, the top 10 institutions control 30.0% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their ABCL positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of ABCL
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Baker Bros. Advisors, LP | 33.01M | 10.11% | 0.0% |
| Capital World Investors | 13.58M | 4.16% | -0.1% |
| Two Sigma Investments, LP | 11.70M | 3.58% | +12.1% |
| TD Waterhouse Canada Inc. | 9.22M | 2.82% | -3.6% |
| Marshall Wace LLP | 8.96M | 2.74% | +370.9% |
| Blackrock Inc. | 5.66M | 1.73% | +48.8% |
| ArrowMark Colorado Holdings LLC | 4.82M | 1.48% | +17.5% |
| Bank of America Corporation | 4.18M | 1.28% | -31.9% |
| Shaw D.E. & Co., Inc. | 3.66M | 1.12% | +7952.5% |
| Alyeska Investment Group, L.p. | 3.06M | 0.94% | +481.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of ABCL
| Fund | Shares | % Held |
|---|---|---|
| SmallCap World Fund Inc | 13.23M | 4.05% |
| iShares Trust-iShares Biotechnology ETF | 1.95M | 0.60% |
| BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 1.26M | 0.39% |
| T. Rowe Price New Horizons Fund, Inc. | 1.05M | 0.32% |
| NORTHERN LIGHTS FUND TRUST III-Counterpoint Quantitative Equity ETF | 971.64K | 0.30% |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 877.50K | 0.27% |
| iShares Trust-iShares Genomics Immunology and Healthcare ETF | 625.39K | 0.19% |
| SPDR INDEX SHARES Fd.S-State Street SPDR PORT. Developed World ex-US E | 573.62K | 0.18% |
| TR PRICE-Price (T.Rowe) New Horizons Trust | 465.60K | 0.14% |
| AMERICAN FUNDS INSURANCE SERIES-SMALLCAP World Fund | 359.75K | 0.11% |
Frequently asked questions
Who is the largest shareholder of AbCellera Biologics?
Baker Bros. Advisors, LP is the largest institutional shareholder of ABCL, owning 10.11% of shares outstanding (33.01M shares) as of its latest 13F filing.
What percentage of AbCellera Biologics is owned by institutions?
Institutions own about 36.8% of ABCL shares and 47.0% of the public float.
How much of AbCellera Biologics do insiders own?
Insiders, such as officers and directors, own about 21.74% of ABCL shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.